1. Wack S., Patton T., Ferris L.K.: COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol 2021, 85, 1274-1284.
2.
Sinclair R., Thirthar Palanivelu V.: Tildrakizumab for the treatment of psoriasis. Expert Rev Clin Immunol 2019, 15, 5-12.
3.
Aryanian Z., Balighi K., Hatami P., Goodarzi A., Mohandesi N.A., Afshar Z.M.: SARS-CoV-2 vaccination and practical points in psoriasis patients: a narrative review. Dermatol Ther 2022, 35, e15430.
4.
Diotallevi F., Campanati A., Radi G., Martina E., Rizzetto G., Barbadoro P., et al.: Vaccines against SARS-CoV-2 in psoriasis patients on immunosuppressive therapy: implications of vaccination nationwide campaign on clinical practice in Italy. Dermatol Ther 2021, 11, 1889-1903.
5.
Gisondi P., Geat D., Naldi L., Piaserico S.L.: Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. J Eur Acad Dermatol Venereol 2021, 35, e361-e362.
6.
Geisen U.M., Berner D.K., Tran F., Sumbul M., Vullriede L., Ciripoi M., et al.: Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021, 80, 1306-1311.
7.
Deepak P., Kim W., Paley M.A., Yang M., Carvidi A.B., Demissie E.G., et al.: Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2 : a prospective cohort study. Ann Intern Med 2021, 174, 1572-1585.
8.
Geisen U.M., Rose R., Neumann F., Ciripoi M., Vullriede L., Reid H.M., et al.: The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade. J Med Virol 2022, 94, 5780-5789.
9.
Geisen U.M., Sümbül M., Tran F., Berner D.K., Reid H.M., Vullriede L., et al.: Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open 2021, 7, e002008.
10.
Bugatti S., De Stefano L., Balduzzi S., Greco M.I., Luvaro T., Cassaniti I., et al.: Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann Rheum Dis 2021, 80, 1635-1638.
11.
Kappelman M.D., Weaver K.N., Boccieri M., Firestine A., Zhang X., Long M.D.: PREVENT-COVID Study Group. Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease. Gastroenterology 2021, 161, 1340-1343.e2.
12.
Mahil S.K., Bechman K., Raharja A., Domingo-Vila C., Baudry D., Brown M.A., et al.: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol 2022, 4, e42-e52.
13.
Furer V., Eviatar T., Zisman D., Peleg H., Paran D., Levartovsky D., et al.: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021, 80, 1330-1338.
14.
Graceffa D., Sperati F., Bonifati C., Spoletini G., Lora V., Pimpinelli F., et al.: Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics. Front Med 2022, 9, 961904.
15.
Piros É.A., Cseprekál O., Görög A., Hidvégi B., Medvecz M., Szabó Z., et al.: Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-prospective observational cohort study. Dermatol Ther 2022, 35, e15408.
16.
Gelfand J.M., Armstrong A.W., Bell S., Anesi G.L., Blauvelt A., Calabrese C., et al.: National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 2021, 84, 1254-1268.
17.
Lafon E., Jäger M., Bauer A., Reindl M., Bellmann-Weiler R., Wilflingseder D., et al.: Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. J Allergy Clin Immunol 2022, 149, 1242-1252.e12.
18.
Ramos A., Cardoso M.J., Ribeiro L., Guimarães J.T.: Assessing SARS-CoV-2 neutralizing antibodies after BNT162b2 vaccination and their correlation with SARS-CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. Diagnostics 2022, 12, 205.
19.
Higashimoto Y., Kozawa K., Miura H., Kawamura Y., Ihira M., Hiramatsu H., et al.: Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Hum Vaccin Immunother 2022, 18, 2105611.
20.
Wagner A., Garner-Spitzer E., Schötta A.M., Orola M., Wessely A., Zwazl I., et al.: SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients - a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol 2022, 13, 889138.
21.
Hsu C.M., Weiner D.E., Manley H.J., Aweh G.N., Ladik V., Frament J., et al.: Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months. Clin J Am Soc Nephrol 2022, 17, 403-413.
22.
Obeid M., Suffiotti M., Pellaton C., Bouchaab H., Cairoli A., Salvadé V., et al.: Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol 2022, 8, e220446.
23.
Hussein K., Dabaja-Younis H., Szwarcwort-Cohen M., Almog R., Leiba R., Weissman A., et al.: Third BNT162b2 vaccine booster dose against SARS-CoV-2-induced antibody response among healthcare workers. Vaccines (Basel) 2022, 10, 1741.
24.
Naaber P., Tserel L., Kangro K., Sepp E., Jürjenson V., Adamson A., et al.: Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021, 10, 100208.
25.
Quast I., Tarlinton D.: B cell memory: understanding COVID-19. Immunity 2021, 54, 205-210.
26.
Passenberg M., Authorsen-Grudmann R., Frey A., Korth J., Zmudzinski J., Anastasiou O.E., et al.: Durability of immune response after application of a third dose of SARS-CoV-2 vaccination in liver transplant recipients. Vaccines (Basel) 2023, 11, 572.
27.
Balsby D., Nilsson A.C., Petersen I., Lindvig S.O., Davidsen J.R., Abazi R., et al.: Humoral immune response following a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients compared with matched controls. Front Immunol 2022, 13, 1039245.
28.
Ogrič M., Žigon P., Podovšovnik E., Lakota K., Sodin-Semrl S., Rotar Ž., et al.: Differences in SARS-CoV-2-specific antibody responses after the first, second, and third doses of BNT162b2 in naïve and previously infected individuals: a 1-year observational study in healthcare professionals. Front Immunol 2022, 13, 876533.
29.
Simon D., Tascilar K., Fagni F., Kronke G., Kleyer A., Meder C., et al.: SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2021, 80, 1312-1316.
30.
Wieske L., van Dam K.P.J., Steenhuis M., Stalman E.W., Kummer L.Y.L., van Kempen Z.L.E., et al.: Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol 2022, 4, e338-e350.
31.
Pardi N., Hogan M.J., Porter F.W., Weissman D.: mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 2018, 17, 261-279.
32.
Haberman R.H., Herati R.S., Simon D., Samanovic M., Blank R.B., Tuen M., et al.: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021, 80, 1339-1344.
33.
Liu X., Shaw R.H., Stuart A.S.V., Greenland M., Aley P.K., Andrews N.J., et al.: Com-COV Study Group. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021, 398, 856-869.
34.
Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., et al.; Com-COV2 Study Group: Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022, 399, 36-49.
35.
Lim S.Y., Yoon Y.I., Kim J.Y., Tak E., Song G.W., Kim S.H., et al.: Antibody response induced by two doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in liver transplant recipients. Immune Netw 2022, 22, e24.
36.
Thakkar A., Gonzalez-Lugo J.D., Goradia N., Gali R., Shapiro L.C., Pradhan K., et al.: Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021, 39, 1081-1090.e2.
37.
Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., et al.: Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021, 385, 1474-1484.
38.
Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., et al.: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021, 27, 1205-1211.
39.
Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., et al.: Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, eabf4063.
